666844-68-4

Upstream product

• 170991-34-1 4-(2-benzyloxyethyl)-1-bromobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 1408168-73-9 potassium [2-(benzyloxy)ethyl]-trifluoroboranuide 
• 104-88-1 4-chlorobenzaldehyde 
• 1122-91-4 4-bromo-benzaldehyde 
• 1462-37-9 bromoethyl-2-benzyl ether 
• 137297-51-9 2-(2-(benzyloxy)ethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Downstream Products

• 735266-17-8 3-{4-[2-(benzyloxy)ethyl]phenyl}-2-(4-methoxyphenyl)-2-propenoic acid 
• 666844-67-3 [4-(2-benzyloxyethyl)phenyl]methanol 

Relevant academic research and scientific papers

Suzuki-Miyaura cross-coupling of potassium alkoxyethyltrifluoroborates: Access to aryl/heteroarylethyloxy motifs

The introduction of an alkoxyethyl moiety onto aromatic substructures has remained a long-standing challenge for synthetic organic chemists. The main reasons are the inherent instability of alkoxyethylmetallic species and the lack of general procedures to access them. A new method utilizing a cross-coupling strategy based on the exceptional properties of organotrifluoroborates has been developed, and the method allows an easy and efficient installation of this unit on a broad range of aryl and heteroaryl bromides.

PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents -RB, -CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.,; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE

A compound of the formula (I): wherein R1 is cycloalkyl, etc; R2 is (lower)alkoxy, etc; R3 is (lower)alkylene, etc; R4 is (lower)alkylene, etc; R5 is hydroxy, etc; X is "0", "S", "SO", or "S02"; Y is "CH" or "N"; n is 0 or 1; or pharmaceutically acceptable salts thereof, which are useful as a medicament

Inhibitor of cox

A compound of the formula (I): wherein R1 is cycloalkyl, etc; R2 is (lower)alkoxy, etc; R3 is (lower)alkylene, etc; R4 is (lower)alkylene, etc; R5 is hydroxy, etc; X is “O”, “S”, “SO”, or “SO2”; Y is “CH” or “N”; n is 0 or 1; or pharmaceutically acceptable salts thereof, which are useful as a medicament.